No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.

• Allgens Medical Technology Co. Ltd.
• Tellgen Corporation
• Treace Medical Concepts, Inc.
• Anika Therapeutics, Inc.
• Senseonics Holdings, Inc.
• InnoCare Optoelectronics Corporation
• United Orthopedic Corporation
• Fischer Medical Ventures Ltd.